uniQure NV (NASDAQ:QURE) shares shot up 7.8% during mid-day trading on Monday . The company traded as high as $8.86 and last traded at $8.85, with a volume of 276,976 shares changing hands. The stock had previously closed at $8.21.

A number of brokerages recently issued reports on QURE. Jefferies Group restated a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. Oppenheimer Holdings Inc. restated a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. Leerink Swann restated a “buy” rating on shares of uniQure NV in a report on Sunday, June 12th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a research note on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $28.10.

The stock has a 50 day moving average of $7.83 and a 200-day moving average of $11.49. The stock’s market cap is $220.14 million.

uniQure NV (NASDAQ:QURE) last released its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. On average, equities research analysts anticipate that uniQure NV will post ($3.50) EPS for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.